A股異動 | 寧科生物跌停 子公司停產或被ST
格隆匯4月6日丨寧科生物(600165.HK)跌停,報4.89元,總市值33億元。4月5日晚,由新日恒力更名而來的寧科生物,突然爆雷!公司公吿,原計劃對公司控股子公司中科新材增資3億元的濟南長悦,遲遲沒有履行增資義務,該違約導致公司控股子公司中科新材臨時停產。公司正在積極籌措,尋找融資渠道,但目前尚未有明確的解決方案。中科新材是寧科生物重要子公司,2022年三季報顯示,其貢獻了公司超七成營業收入。如果中科新材未能在3個月內恢復生產,公司存在被實施“其他風險警示(ST)”的風險。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.